Metabolic dysfunctionassociated steatotic liver disease (MASLD) is often asymptomatic, and when symptoms do present, they are nonspecific and rarely trigger alarm bells. The primary care setting is often the first line of...
Read More
These results underscored the efficacy of bariatric interventions in ameliorating both imaging and histologic markers of MASLD.
Read More
Study findings suggest that exercise can mitigate liver fibrosis markers effectively, highlighting its role as a weight-neutral intervention supported by accessible biomarkers for widespread clinical use.
Read MoreThe prevalence of MASH is increasing worldwide. A model created at the Cleveland Clinic Lerner College of Medicine projects that the number of Metabolic dysfunction associated steatotic liver disease (MASLD) cases is going to...
Read MoreMASH poses significant risks as it can lead to advanced liver fibrosis, cirrhosis, and hepatocellular carcinoma. The prevalence of MASH closely mirrors that of metabolic syndrome (MetS), which exacer bates the risk of advanced...
Read More
